Apremilast is an inhibitor of phosphodiesterase 4 (PDE4) that is clinically used to treat psoriasis and psoriatic arthritis. Apremilast exhibits anti-inflammatory and immunomodulatory activities, increasing levels of cAMP and IL-10 and decreasing levels of iNOS, IL-23, and TNF-α in vitro and in vivo. An analog of thalidomide.
| Cas No. | 608141-41-9 |
|---|---|
| Purity | ≥98% |
| Formula | C23H25N2O7S |
| Formula Wt. | 460.51 |
| IUPAC Name | N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide |
| Synonym | CC-10004; CC10004 |
| Melting Point | 156.1°C |
| Solubility | Insoluble in water. Slightly soluble in ethanol. Soluble in acetone (20mg/mL), DMSO (80 mg/mL). |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014 Sep;26(9):2016-29. PMID: 24882690.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. PMID: 22257911.
